Early cannabis use was a strong independent predictor of subclinical hypomania symptoms at age 16

In a cohort of 1,632 Danish children followed from age 11 to 16, early cannabis use (by age 15) was the strongest independent predictor of subclinical hypomania at age 16, with a 3-fold increased risk.

Nielsen, Louise Gunhard et al.·PloS one·2021·Strong EvidenceLongitudinal Cohort
RTHC-03382Longitudinal CohortStrong Evidence2021RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Longitudinal Cohort
Evidence
Strong Evidence
Sample
Not reported

What This Study Found

Cannabis use by age 15 was a strong independent predictor of self-reported subclinical hypomania at age 16 (RR 3.14, 95% CI 1.93-5.10), after adjusting for age 11 psychopathology and other precursors. Psychotic experiences at age 11 (RR 2.06) and emotional disorders (RR 1.77) also predicted age 16 hypomania. Subclinical hypomania at age 11 showed modest continuity with age 16 (RR 1.89).

Key Numbers

1,632 at age 11; 893 reassessed at age 16; cannabis by age 15 RR 3.14; psychotic experiences RR 2.06; emotional disorders RR 1.77; age 11 SHM → age 16 SHM RR 1.89

How They Did This

Longitudinal study from the Copenhagen Child Cohort 2000. 1,632 preadolescents were assessed for subclinical hypomania and clinical correlates at age 11 via semi-structured interviews. 893 were reassessed at age 16 with self-report (HCL-32). Cannabis use by age 15 was assessed at age 16.

Why This Research Matters

Subclinical hypomania in adolescence may be an early marker of bipolar disorder risk. Finding that early cannabis use is the strongest modifiable predictor provides a potential intervention target.

The Bigger Picture

Cannabis use standing out as the strongest independent predictor of subclinical hypomania, even stronger than pre-existing psychotic experiences, adds to growing evidence that early cannabis use may specifically increase risk for bipolar spectrum pathology.

What This Study Doesn't Tell Us

Cannabis use assessed retrospectively at age 16 for use by age 15. Self-reported hypomania at age 16 may differ from interview-based assessment. Cannot determine whether cannabis caused hypomania or shared vulnerability explains both.

Questions This Raises

  • ?Does preventing early cannabis use reduce bipolar disorder risk?
  • ?Is the association specific to cannabis or would other substances show similar patterns?
  • ?Could subclinical hypomania at 16 predict full bipolar disorder later?

Trust & Context

Key Stat:
3.14x risk of subclinical hypomania at 16 with early cannabis use
Evidence Grade:
Large population-based longitudinal cohort with structured assessments, though self-report at age 16 and retrospective cannabis assessment are limitations.
Study Age:
Published in 2021.
Original Title:
Precursors of self-reported subclinical hypomania in adolescence: A longitudinal general population study.
Published In:
PloS one, 16(6), e0253507 (2021)
Database ID:
RTHC-03382

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-ControlFollows or compares groups over time
This study
Cross-Sectional / Observational
Case Report / Animal Study

Follows a group of people over time to track how outcomes develop.

What do these levels mean? →

Frequently Asked Questions

Can cannabis trigger early signs of bipolar disorder?

This study found early cannabis use was the strongest independent predictor of subclinical hypomania at age 16, with a 3-fold increased risk. However, whether cannabis directly triggers these symptoms or shares underlying vulnerability factors is not established.

What is subclinical hypomania?

Subclinical hypomania includes symptoms like elevated mood, increased energy, and reduced need for sleep that are common in adolescence but may be early markers of bipolar disorder risk when persistent or severe.

Read More on RethinkTHC

Cite This Study

RTHC-03382·https://rethinkthc.com/research/RTHC-03382

APA

Nielsen, Louise Gunhard; Køster Rimvall, Martin; Van Os, Jim; Verhulst, Frank; Rask, Charlotte Ulrikka; Skovgaard, Anne Mette; Olsen, Else Marie; Jeppesen, Pia. (2021). Precursors of self-reported subclinical hypomania in adolescence: A longitudinal general population study.. PloS one, 16(6), e0253507. https://doi.org/10.1371/journal.pone.0253507

MLA

Nielsen, Louise Gunhard, et al. "Precursors of self-reported subclinical hypomania in adolescence: A longitudinal general population study.." PloS one, 2021. https://doi.org/10.1371/journal.pone.0253507

RethinkTHC

RethinkTHC Research Database. "Precursors of self-reported subclinical hypomania in adolesc..." RTHC-03382. Retrieved from https://rethinkthc.com/research/nielsen-2021-precursors-of-selfreported-subclinical

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.